ABCA17 Inhibitors

Chemical inhibitors of ATP-binding cassette, sub-family A member 17 (ABCA17) include a variety of compounds that can inhibit the function of this protein through distinct mechanisms. Verapamil, a well-known calcium channel blocker, can also bind to the nucleotide-binding domain of ABCA17, obstructing ATP hydrolysis and thus the energy-dependent transport of substrates. Similarly, Quercetin, a plant flavonol, directly interacts with the ATP-binding sites of ABCA17, disrupting the ATPase activity essential for substrate transport. Elacridar and Tariquidar are another set of inhibitors that alter the protein's conformation and bind to allosteric sites, respectively, both resulting in the non-competitive inhibition of substrate transport. Zosuquidar and Laniquidar, on the other hand, inhibit ABCA17 by binding to its nucleotide-binding domain and transmembrane domains, respectively, with the former blocking ATP hydrolysis and the latter obstructing substrate translocation across the cell membrane.

Furthermore, Reserpine can inhibit ABCA17 by preventing substrate binding, which is a crucial step for initiating the transport process. Progesterone, a steroid hormone, interacts with regulatory sites on ABCA17, diminishing its ATPase activity and thus reducing substrate transport. Cyclosporine A and Glibenclamide both target the ATP-binding domain of ABCA17, with Cyclosporine A blocking the initiation of the transport cycle and Glibenclamide obstructing the hydrolysis of ATP. Rifampicin and MK-571 exert their inhibitory effects through selective binding to ABCA17 and competitive inhibition of substrate binding, respectively, with the former impairing the transport efficiency and the latter preventing substrate translocation across the membrane. Collectively, these inhibitors employ various methods to inhibit the functional activity of ABCA17, ranging from altering its conformation to obstructing ATP hydrolysis, and from preventing substrate binding to reducing ATPase activity. Each chemical's interaction with ABCA17 leads to a decrease in the protein's ability to transport substrates across the cell membrane, demonstrating diverse mechanisms of inhibition.